DOCSLIB.ORG

Market Deep Dive Report Longevity Therapeutics June 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Market Deep Dive Report Longevity Therapeutics June 2020 Market Deep Dive Report Longevity Therapeutics June 2020 Contents 1. Summary 3 2. Market Overview 3 2.1 Pitchbook Statistics 4 3. Technology Overview 5 3.1 The Biology of Aging 5 3.2 Current Approaches 6 3.3 Late stage privates & publics 8 5. Historical Context, Key Trends, & Future Development 9 5.1 History 9 5.2 Present day status 9 5.3 Top People and Labs 10 5.4 Top VCs and Funding Sources: 10 5.5 Future Predictions 11 6. Opportunities 11 6.1 Startups to Watch 11 6.3 Industry challenges 13 7. Conclusions 14 7.1 Vertical Strengths 14 7.2 Vertical Weaknesses 14 7.3 Opportunity Cost of Capital 14 7.4 Investment Thesis Areas 15 8. References 15 2 1. Summary Aging and longevity focused startups are still in risky and exploratory phases. Most aging science has only occurred in animal models, and the few compounds that have progressed in clinical trials have failed in Phase III or are currently testing. The biology of aging is inconclusive and there are major concerns about side effects including cancer and other quality of life aspects when interventions are given. The market for aging therapeutics is unique in that the demand is invariably high, yet there has been slow adoption by VC firms and large biopharma companies to partner, invest, and develop such technologies. This may be due to a history of high profile failures and a more sober realization that the current stage of biogerontology research is not mature enough to afford the expenses of clinical trials and the current biopharma R&D lifecycle. Indeed, it seems that the field is in the early target ID stage, driven primarily by methodological scientific progress rather than high throughput screening approaches used to identify most pipeline ready compounds. Still, there has been a resurgence of interest, powered by the excitement of some high profile clinical trials, ever increasing research spending, and a philosophical shift of many to view aging as a disease rather than an inevitability. The establishment of new longevity focused funds as well as some strong recent funding rounds has encouraged founders to start ventures and commercialize their research. However, due to existing biological complexity and uncertainty, longevity remains a highly turbulent field to invest in. Ultimately, success as a startup is highly dependent on the chosen biological approach, as few if any have developed biology distanced platform approaches to discovery therapeutics. 2. Market Overview The global longevity and anti-senescence therapies market will grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% from 2018-2023. The key growth drivers are increasing funding and progress in aging research and a wealthy aging population. Life extension is unlike any normal demand curve. There will be a tremendous growth in market opportunity because of an aging Boomer population in the U.S. and the world average lifespan also increasing annually. Using a model of future health and spending in the USA, the effect of delayed aging resulting in 2.2 years additional life expectancy would yield US $7 trillion 3 in savings over 50 years. The median wealth of US families aged 62 years or older is over US $200, 000, compared with US $100,000 and US $14,000 for middle-aged and young families, respectively. This may in part be responsible for the increase in investment in even non-traditional therapies and DTC products and services aimed at extending healthy lifespan. Still, the market for longevity therapies has been dampened by the discouragement of past failures. The most prominent example was GSK’s acquisition of Sirtris for $720 million in April 2008, whose leading compound resveratrol was hyped to have unprecedented success in pre-clinical modeling. Five years after the acquisition, GSK shut down Sirtris due to lack of efficacy. This comes with a string of more recent high visibility companies that have failed to reach investor expectations. Human Longevity Inc., founded in 2013 and previously headed by Craig Venter was once worth $1.5 billion and now has dropped to a post-valuation of $40 million. AgeX Therapeutics, founded in 2017 was once worth $68 million and IPOed in late 2018. It currently has a market cap of $28 million and is in risk of getting delisted by the NYSE. Aging has received funding from atypical investors. Historically, the field has received interest from tech innovators and billionaire investors including Peter Thiel (Unity Biotech), Jeff Bezos (Unity Biotech), Google (Calico), Adam Neumann (Life Biosciences), Jim Mellon (Juvenescence). The largest aging focused company, Samumed, is worth over $12 billion and has been funded primarily by private equity investors. Indeed, VCs have only recently viewed aging as a field worthy of investment. In particular, high impact investors including a16z and First Round have recently made investments into early stage aging startups Bioage and Spring Discovery, respectively. Among other deals, Juvenescence got a $100 million series B in August 2019. Life Biosciences got a $50 million series B in January 2019. There has recently been progress made. The first in-human trials of senolytics are ongoing. Nutraceutical and stem cell regenerative medicine trials are ongoing. Samumed is starting Phase III trials for OA. Even more promising for aging becoming an accepted indication, a Nature Aging journal was just set up and a trial for metformin was just approved using aging as a clinical endpoint, which is a tremendous step towards regulatory approval for aging focused therapies. 2.1 Pitchbook Statistics ● Quick stats (All time) ○ No. Companies: 25 ○ No. Deals: 82 ○ No. Investors: 101 ○ Largest deal: $438 M (Samumed) ● Deal count (TTM): 8 ● Most active VCs by deal count: ARCH Venture Partners, Kizoo Technology Capital, Fidelity Management, Bold Capital Partners, EcoR1 Capital, 4 Stage Average Round Size Average Post Valuation Seed $1.35 M $4.63 M A $9.68 M $37.27 M B $48 M $255.75 M C,D,E,F $37.52 M $259 M 3. Technology Overview 3.1 The Biology of Aging Most diseases accelerate with age, both in terms of incidence and severity. Cellular damage accrues over time, and as bodily repair mechanisms become worse and worse at fixing such damage, cancers, heart disease, autoimmune diseases, and others become more frequent and eventually cause death. A robust collection of in-vivo data has demonstrated that alleviating age related biological damage decreases risk of diabetes, neurodegenerative disease, and even cancer. In a hallmark review, researchers have developed 9 ‘hallmarks of aging’, which have been ​ ​ targets of therapeutic interventions. At current stages of research, there are no indications of which are may be more therapeutically promising than others. As a result, a spectrum of companies targeting different aspects of aging biology have arisen. 5 Hallmarks of Aging 1Stem Cell Activities of the 4 types of stem cells, which all help in regenerating new Exhaustion tissue cells, decline with aging. Altered Communication between cells is disrupted with age, resulting in Intercellular inflammation and tissue damage. Communication Genomic Throughout one’s life, both internal and external factors that cause Instability genetic damage start to build up in the body. This is known to accelerate aging. Telomere Telomeres – the protective “caps” located at the ends of our chromosomes Attrition (which house our genetic material) – start getting shorter each time a cell divides. Over time, this results in cells not being able to divide anymore, which can lead to disease. Epigenetic There are changes in gene expression (not changes to the DNA itself) via Alterations an individual’s life experiences or environmental factors which affect aging. Loss of With age, cellular proteins become misfolded and therefore, lose their Proteostasis homeostatic functions. A build up of these damaged proteins is observed with aging or age-related diseases. Deregulated There are metabolism-regulating pathways, whose proteins (e.g. mTOR, nutrient sensing sirtuins) are influenced by nutrient levels and also implicated in promoting aging. Mitochondrial When the mitochondria (considered the energy powerhouse responsible Dysfunction for regulating metabolism in our bodies) starts to malfunction with age. Cellular “Older” cells can’t be cleared out as fast and their build up can lead to Senescence harmful health effects. 3.2 Current Approaches Current approaches to therapies can be segmented into pharmacological treatments and cell and blood based therapies. The industry has favored the more traditional pharmacological approach, but with the applicability of stem cell research in other indications, regenerative cell based therapies have recently been of interest. Pharmacological 1 Table from CB Insights 6 On the pharmacological side, the current iteration of therapeutics have hoped to target molecules and targets that are over or under-expressed in aged individuals. These have ranged from nutraceutical supplements, repurposed diabetic medication, selective elimination of cells, and compounds to make cells live and last longer. The most promising and widely studied options have been rapamycin analogs, which modulate cell metabolism, and senolytics, which selectively eliminate senescent cells. Starting with the nutraceuticals, Elysium Health has developed Basis, a pill containing a ​ ​ powerful antioxidant and a precursor to NAD+, which has been demonstrated in lab experiments to promote cellular health and longevity. NAD+ levels decrease with age and boosting NAD+ metabolism has been shown to boost lifespan in numerous model organisms. Basis has been tested clinically to increase NAD+ levels, and Elysium has announced a follow-up study to study the effects of NAD+ levels on epigenetic aging in humans. This study was expected to be finished in May, however no updates have been posted. Basis is sold DTC as a supplement and thus has bypassed most costly FDA regulatory requirements.
Load more

Recommended publications
  • Incorporating Authentic Video Into Language-Learning Mobile Applications
    Incorporating Authentic Video into Language-learning Mobile Applications Andrew Watabe A project submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Arts J. Paul Warnick, Chair Rob Alan Martinsen Rob Reynolds Center for Language Studies Brigham Young University Copyright © 2021 Andrew Watabe All Rights Reserved ABSTRACT Incorporating Authentic Video into Language-learning Mobile Applications Andrew Watabe Center for Language Studies, BYU Master of Arts Authentic content in language materials can provide learners with meaningful contexts that enhance language learning (Shrum & Glisan, 2016). This project seeks to create a Japanese- learning iOS app that teaches language directly from authentic Japanese YouTube videos. The app provides a video library where users can find videos on a variety of topics such as food, music, beauty, and games. Each video features video captions, vocabulary exercises, and grammar drills based on the language used in the video. Students enrolled in Japanese classes at Brigham Young University were asked to test out the app and provide feedback on their experience. The participants enjoyed the authentic content and found the written transcripts of the videos to be helpful to their learning. They also requested additional content and features to improve the app. Based on the participants’ comments, we created a plan of action including future updates for the app. Keywords: CALL, authentic texts, Japanese, scaffolding, mobile apps, YouTube
    [Show full text]
  • Cellular Senescence Promotes Skin Carcinogenesis Through P38mapk and P44/P42mapk Signaling
    Author Manuscript Published OnlineFirst on July 8, 2020; DOI: 10.1158/0008-5472.CAN-20-0108 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Cellular senescence promotes skin carcinogenesis through p38MAPK and p44/p42 MAPK signaling Fatouma Alimirah1, Tanya Pulido1, Alexis Valdovinos1, Sena Alptekin1,2, Emily Chang1, Elijah Jones1, Diego A. Diaz1, Jose Flores1, Michael C. Velarde1,3, Marco Demaria1,4, Albert R. Davalos1, Christopher D. Wiley1, Chandani Limbad1, Pierre-Yves Desprez1, and Judith Campisi1,5* 1Buck Institute for Research on Aging, Novato, CA 94945, USA 2Dokuz Eylul University School of Medicine, Izmir 35340, Turkey 3Institute of Biology, University of the Philippines Diliman, College of Science, Quezon City 1101, Philippines 4European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, the Netherlands 5Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA *Lead Contact: Judith Campisi, Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA; Email: [email protected] or [email protected]. Telephone: 1-415-209-2066; Fax: 1-415-493-3640 Running title: Senescence and skin carcinogenesis Key words: doxorubicin, senescence-associated secretory phenotype, squamous cell carcinoma, microenvironment, inflammation, transgenic mice, tumorspheres Conflict of Interests JC is a co-founder of Unity Biotechnology and MD owns equity in Unity Biotechnology. All other authors declare no competing financial interests. Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 8, 2020; DOI: 10.1158/0008-5472.CAN-20-0108 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • SENS-Research-Foundation-2019
    by the year 2050, cardiovascular an estimated 25-30 the american 85 percent of adults disease years and older age 85 or older remains the most population will suffer from common cause of 2 1 2 dementia. death in older adults. triple. THE CLOCK IS TICKING. By 2030, annual direct The estimated cost of medical costs associated dementia worldwide was 62% of Americans with cardiovascular $818 billion diseases in the united over age 65 have in 2015 and is states are expected to more than one expected to grow to rise to more than chronic condition.1 3 $2 trillion $818 billion. by 2030.1 References: (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732407/, (2) https://www.who.int/ageing/publications/global_health.pdf, (3) https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity sens research foundation board of directors Barbara Logan Kevin Perrott Bill Liao Chairperson Treasurer Secretary Michael Boocher Kevin Dewalt James O’Neill Jonathan Cain Michael Kope Frank Schuler 02 CONTENTS 2019 Annual Report 04 Letter From The CEO 06 Outreach & Fundraising 08 Finances 09 Donors erin ashford photography 14 Education 26 Investments 20 Conferences & Events 30 Research Advisory Board 23 Speaking Engagements 31 10 Years Of Research 24 Alliance 32 MitoSENS 34 LysoSENS 35 Extramural Research 38 Publications 39 Ways to Donate cover Photo (c) Mikhail Leonov - stock.adobe.com special 10th anniversary edition 03 FROM THE CEO It’s early 2009, and it’s very late at night. Aubrey, Jeff, Sarah, Kevin, and Mike are sitting around a large table covered in papers and half-empty food containers.
    [Show full text]
  • 5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
    FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations
    [Show full text]
  • Read Our New Annual Report
    The seeds of a concept. The roots of an idea. The potential of a world free of age-related disease. Photo: Sherry Loeser Photography SENS Research Foundation Board of Directors Barbara Logan, Chair Bill Liao, Secretary Kevin Perrott, Treasurer Michael Boocher Jonathan Cain Kevin Dewalt Michael Kope Jim O’Neill Frank Schüler Sherry Loeser Photography 2 Contents CEO Letter (Jim O’Neill) 4 Finances 5 Donors 6 - 7 Fundraising & Conferences 8 - 9 Around the World with Aubrey de Grey 10 Outreach 11 Founding CEO Tribute & Underdog Pharmaceuticals 12 - 13 Investments 14 Welcome New Team Members 15 Education 16 - 17 Publications & Research Advisory Board 18 Research Summaries 19 - 22 Ways to Donate 23 The SRF Team Front row: Anne Corwin (Engineer/Editor), Amutha Boominathan (MitoSENS Group Lead), Alexandra Stolzing (VP of Research), Aubrey de Grey (Chief Science Officer), Jim O’Neill (CEO), Bhavna Dixit (Research Associate). Center row: Caitlin Lewis (Research Associate), Lisa Fabiny-Kiser (VP of Operations), Gary Abramson (Graphics), Maria Entraigues-Abramson (Global Outreach Coordinator), Jessica Lubke (Administrative Assistant). Back row: Tesfahun Dessale Admasu (Research Fellow), Amit Sharma (ImmunoSENS Group Lead), Michael Rae (Science Writer), Kelly Protzman (Executive Assistant). Not Pictured: Greg Chin (Director, SRF Education), Ben Zealley (Website/Research Assistant/ Deputy Editor) Photo: Sherry Loeser Photography, 2019 3 From the CEO At our 2013 conference at Queens College, Cambridge, I closed my talk by saying, “We should not rest until we make aging an absurdity.” We are now in a very different place. After a lot of patient explanation, publication of scientific results, conferences, and time, our community persuaded enough scientists of the feasibility of the damage repair approach to move SENS and SENS Research Foundation from the fringes of scientific respectability to the vanguard of a mainstream community of scientists developing medical therapies to tackle human aging.
    [Show full text]
  • Common Labor, Common Lives: the Social Construction of Work in Four Communal Societies, 1774-1932 Peter Andrew Hoehnle Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2003 Common labor, common lives: the social construction of work in four communal societies, 1774-1932 Peter Andrew Hoehnle Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the United States History Commons Recommended Citation Hoehnle, Peter Andrew, "Common labor, common lives: the social construction of work in four communal societies, 1774-1932 " (2003). Retrospective Theses and Dissertations. 719. https://lib.dr.iastate.edu/rtd/719 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Common labor, common lives: The social construction of work in four communal societies, 1774-1932 by Peter Andrew Hoehnle A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Agricultural History and Rural Studies Program of Study Committee: Dorothy Schwieder, Major Professor Pamela Riney-Kehrberg Christopher M. Curtis Andrejs Plakans Michael Whiteford Iowa State University Ames, Iowa 2003 © Copyright Peter Andrew Hoehnle, 2003. All rights reserved. UMI Number: 3118233 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction.
    [Show full text]
  • Calico Global V. Calico
    Case 2:17-cv-00643-JRG Document 1 Filed 09/12/17 Page 1 of 13 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION CALICO GLOBAL PTY LTD., Plaintiff, v. Civil Action No.: 2:17-cv-00643 CALICO LLC. GOOGLE, INC., and JURY TRIAL DEMANDED ALPHABET INC., Defendants. PLAINTIFF’S COMPLAINT FOR TRADEMARK INFRINGEMENT Plaintiff CALICO GLOBAL PTY LTD. (hereinafter referred to as “Plaintiff”) brings this suit for trademark infringement Defendants, CALICO LLC (“Calico”). GOOGLE, INC., (“Google”) and ALPHABET INC. (“Alphabet”) (collectively, “Defendants”), and alleges as follows: NATURE OF ACTION 1. This is an action for trademark infringement based upon Defendants having improperly and willfully used a mark nearly identical to Plaintiff’s trademark CALICO, with trademark Registration No. 3,680,863, without permission, thereby causing customer confusion and unfairly competing with Plaintiff by the improper use of Plaintiff’s Trademark. JURISDICTION AND VENUE 2. This action arises under the trademark laws of the United States. 15 U.S.C. §§ 1051 et seq. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a) and (b), as well as 15 U.S.C. §1121. Case 2:17-cv-00643-JRG Document 1 Filed 09/12/17 Page 2 of 13 PageID #: 2 3. Personal jurisdiction exists over the Defendants because they conduct substantial business in Texas, and have ongoing and systematic contacts with this District, and therefore have sufficient contacts such that it would not offend traditional notions of fair play and substantial justice to subject Defendants to suit in this forum.
    [Show full text]
  • Cellular Senescence and Apoptosis: How Cellular Responses Might Influence Aging Phenotypes
    Experimental Gerontology 38 (2003) 5–11 www.elsevier.com/locate/expgero Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes Judith Campisia,b,* aLife Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA 94720, USA bBuck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA Received 20 May 2002; accepted 28 May 2002 Abstract Aging in complex multi-cellular organisms such as mammals entails distinctive changes in cells and molecules that ultimately compromise the fitness of adult organisms. These cellular and molecular changes lead to the phenotypes we recognize as aging. This review discusses some of the cellular and molecular changes that occur with age, specifically changes that occur as a result of cellular responses that evolved to ameliorate the inevitable damage that is caused by endogenous and environmental insults. Because the force of natural selection declines with age, it is likely that these processes were never optimized during their evolution to benefit old organisms. That is, some age- related changes may be the result of gene activities that were selected for their beneficial effects in young organisms, but the same gene activities may have unselected, deleterious effects in old organisms, a phenomenon termed antagonistic pleiotropy. Two cellular processes, apoptosis and cellular senescence, may be examples of antagonistic pleiotropy. Both processes are essential for the viability and fitness of young organisms, but may contribute to aging phenotypes, including certain age-related diseases. q 2002 Elsevier Science Inc. All rights reserved. Keywords: Antagonistic pleiotropy; Apoptosis; Cancer; Cellular senescence; DNA damage response; Neurodegeneration; p53; Telomeres 1.
    [Show full text]
  • How to Think and Act Rationally
    1 How to Be Rational: How to Think and Act Rationally David Robert [email protected] Abstract: This paper is divided into 4 sections. In Sections 1 and 2, I address (1) how to acquire rational belief attitudes and (2) how to make rational choices. Building on Sections 1 and 2, I then answer two of the most pressing questions of our time: (3) Should you be skeptical of climate change? (4) Should you invest in life-extension medical research? It has always appalled me that really bright scientists almost all work in the most competitive fields, the ones in which they are making the least difference. In other words, if they were hit by a truck, the same discovery would be made by somebody else about 10 minutes later. —Aubrey de Grey To make rational choices involves choosing courses of action that best serve one’s ends. As a good example, one’s chances of having a positive impact on the world are significantly greater if one focuses one’s efforts on solving the world’s biggest, most urgent problems than if one focuses one’s efforts on solving comparatively small, non-urgent problems that will not ultimately matter in the long run if the biggest, most urgent problems are left unsolved. Therefore, if one’s goal is to make a difference in the world, then it is simply not rational to focus one’s efforts on solving comparatively small, non-urgent problems. It is true that functioning societies do need people working on comparatively small day- to-day problems.
    [Show full text]
  • 321444 1 En Bookbackmatter 533..564
    Index 1 Abdominal aortic aneurysm, 123 10,000 Year Clock, 126 Abraham, 55, 92, 122 127.0.0.1, 100 Abrahamic religion, 53, 71, 73 Abundance, 483 2 Academy award, 80, 94 2001: A Space Odyssey, 154, 493 Academy of Philadelphia, 30 2004 Vital Progress Summit, 482 Accelerated Math, 385 2008 U.S. Presidential Election, 257 Access point, 306 2011 Egyptian revolution, 35 ACE. See artificial conversational entity 2011 State of the Union Address, 4 Acquired immune deficiency syndrome, 135, 2012 Black Hat security conference, 27 156 2012 U.S. Presidential Election, 257 Acxiom, 244 2014 Lok Sabha election, 256 Adam, 57, 121, 122 2016 Google I/O, 13, 155 Adams, Douglas, 95, 169 2016 State of the Union, 28 Adam Smith Institute, 493 2045 Initiative, 167 ADD. See Attention-Deficit Disorder 24 (TV Series), 66 Ad extension, 230 2M Companies, 118 Ad group, 219 Adiabatic quantum optimization, 170 3 Adichie, Chimamanda Ngozi, 21 3D bioprinting, 152 Adobe, 30 3M Cloud Library, 327 Adonis, 84 Adultery, 85, 89 4 Advanced Research Projects Agency Network, 401K, 57 38 42, 169 Advice to a Young Tradesman, 128 42-line Bible, 169 Adwaita, 131 AdWords campaign, 214 6 Affordable Care Act, 140 68th Street School, 358 Afghan Peace Volunteers, 22 Africa, 20 9 AGI. See Artificial General Intelligence 9/11 terrorist attacks, 69 Aging, 153 Aging disease, 118 A Aging process, 131 Aalborg University, 89 Agora (film), 65 Aaron Diamond AIDS Research Center, 135 Agriculture, 402 AbbVie, 118 Ahmad, Wasil, 66 ABC 20/20, 79 AI. See artificial intelligence © Springer Science+Business Media New York 2016 533 N.
    [Show full text]
  • Cellular Senescence and the Senescent Secretory Phenotype: Therapeutic Opportunities
    Cellular senescence and the senescent secretory phenotype: therapeutic opportunities Tamara Tchkonia, … , Judith Campisi, James L. Kirkland J Clin Invest. 2013;123(3):966-972. https://doi.org/10.1172/JCI64098. Review Series Aging is the largest risk factor for most chronic diseases, which account for the majority of morbidity and health care expenditures in developed nations. New findings suggest that aging is a modifiable risk factor, and it may be feasible to delay age-related diseases as a group by modulating fundamental aging mechanisms. One such mechanism is cellular senescence, which can cause chronic inflammation through the senescence-associated secretory phenotype (SASP). We review the mechanisms that induce senescence and the SASP, their associations with chronic disease and frailty, therapeutic opportunities based on targeting senescent cells and the SASP, and potential paths to developing clinical interventions. Find the latest version: https://jci.me/64098/pdf Review series Cellular senescence and the senescent secretory phenotype: therapeutic opportunities Tamara Tchkonia,1 Yi Zhu,1 Jan van Deursen,1 Judith Campisi,2 and James L. Kirkland1 1Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA. 2Buck Institute for Research on Aging, Novato, California, USA. Aging is the largest risk factor for most chronic diseases, which account for the majority of morbidity and health care expenditures in developed nations. New findings suggest that aging is a modifiable risk factor, and it may be feasible to delay age-related diseases as a group by modulating fundamental aging mechanisms. One such mech- anism is cellular senescence, which can cause chronic inflammation through the senescence-associated secretory phenotype (SASP).
    [Show full text]
  • Amended Complaint
    19CV341522 Santa Clara – Civil Electronically Filed 1 OTTINI OTTINI INC B & B , . by Superior Court of CA, FrancisA.Bottini,Jr.(SBN175783) County of Santa Clara, 2 AlbertY.Chang(SBN296065) on 8/16/2019 3:18 PM YuryA.Kolesnikov(SBN271173) 3 Reviewed By: R. Walker 7817IvanhoeAvenue,Suite102 Case #19CV341522 LaJolla,California92037 4 Envelope: 3274669 Telephone:(858)914-2001 5 Facsimile:(858)914-2002 Email:[email protected] 6 [email protected] [email protected] 7 8 COHENMILSTEINSELLERS&TOLLPLLC JulieGoldsmithReiser( ) 9 MollyBowen( ) 1100NewYorkAvenue,N.W.,Suite500 10 Washington,D.C.20005 11 Telephone:(202)408-4600 Facsimile:(202)408-4699 12 Email:[email protected] [email protected] 13 14 15 [AdditionalCounselonSignaturePage] 16 SUPERIORCOURTOFTHESTATEOFCALIFORNIA INANDFORTHECOUNTYOFSANTACLARA 17 18 INREALPHABETINC.SHAREHOLDER LeadCaseNo.19CV341522 19 DERIVATIVELITIGATION 20 CONSOLIDATED 21 STOCKHOLDERDERIVATIVE ThisDocumentRelatesto: COMPLAINTFOR: 22 DEMANDFUTILITYACTION (1)BREACHOFFIDUCIARYDUTY; 23 (2)UNJUSTENRICHMENT; (3)CORPORATEWASTE;and 24 (4)ABUSEOFCONTROL 25 JURYTRIALDEMANDED 26 27 PUBLIC-REDACTSMATERIALSFROMCONDITIONALLYSEALEDRECORD 28 CONSOLIDATEDSTOCKHOLDERDERIVATIVECOMPLAINT 1 TABLE OF CONTENTS 2 I. INTRODUCTION ...................................................................................................... 2 3 II. JURISDICTION AND VENUE ............................................................................... 11 4 III. PARTIES .................................................................................................................
    [Show full text]